NCT00550459View on ClinicalTrials.gov

Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

March 31, 2009

Conditions
Hyponatremia
Interventions
DRUG

Tolvaptan

15-60 mg oral tablet given once a day for 21 days.

DRUG

Placebo

Placebo tablet given once daily for 21 days

Trial Locations (12)

22908

Mitchell Rosner, MD, Charlottesville

29201

Carolina Research Associates, Columbia

30094

Rockdale Medical Research Associates, Conyers

33770

Innovative Research of West FL, Largo

33950

Coastal Nephrology Assoc. Research Center, Punta Gorda

37087

Wayne O. Wells, MD, Lebanon

58106

Lillestol Research, LLC, Fargo

71457

Otis Barnum, DO, Natchitoches

77043

Memorial Clinical Associates, Houston

80907

Pikes Peak Cardiology, Colorado Springs

90250

Sarah. S. Olelewe, MD, Hawthorne

92083

Progressive Clinical Research, Vista

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY